• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Canada·Healthcare·TLRY
Held by 2 Gurus
Share

Tilray Brands, Inc. Stocks

$ 2.53Last Updated 30.10.2026

Issuer Rating

3/7
Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

$ 282.93M

$ 2.53
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

In Guru Portfolios

Steven Cohen

Portfolio Weight (%)

0.0%

Change

+0.00%

Fund

Point72 Asset Management, L.P.

Kenneth Griffin

Portfolio Weight (%)

0.0%

Change

-0.00%

Fund

CITADEL ADVISORS LLC

Manager
Fund
Portfolio Weight (%)
Change
Steven CohenPoint72 Asset Management, L.P.0.0%+0.00%
Kenneth GriffinCITADEL ADVISORS LLC0.0%-0.00%

Latest news

27.05.2026 17:27

Analyst says 'don't bother' with pot stock Tilray, even after Trump's rescheduling

24.04.2026 18:14

Cannabis has been recognized as less dangerous in the US. Why did the shares of companies related to it fall?

23.04.2026 02:30

Pot stocks soar as Axios reports imminent U.S. reclassification of cannabis

19.12.2025 08:30

Despite Trump executive order, pot stocks dip as traders take profit

17.12.2025 18:35

Cannabis stocks rally as Trump 'very strongly' considering reclassifying marijuana

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Tilray Brands, Inc. operates as a consumer lifestyle company primarily involved in the research, cultivation, manufacturing, and worldwide supply of medical cannabis products. Its expansive global footprint includes Canada, the United States, Europe, the Middle East, Africa, and numerous other international regions. The company's business activities are organized into four distinct segments: Beverages, Cannabis, Distribution, and Wellness. Beyond its medical cannabis offerings, Tilray Brands also provides products for adult recreational cannabis markets. The company further diversifies its portfolio by reselling and distributing pharmaceutical and wellness items, as well as producing, marketing, and selling a range of beverage and hemp-derived food products. Its offerings also extend to entertainment products. These varied products are marketed under a vast collection of brand names, featuring prominent labels such as Tilray, Aphria, Broken Coast, SweetWater Brewing, and HEXO, among many others. Tilray Brands utilizes a broad distribution network, selling its products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, governments, and directly to consumers. The company, which was formerly known as Tilray, Inc., officially adopted the name Tilray Brands, Inc. in January 2022. Its corporate headquarters are situated in Leamington, Canada.

Company Valuation

Greatly undervalued
7/7

From both historical and forecast perspectives, the stock is considerably underpriced compared to similar stocks. In particular, the stock is of fair value on EV/EBITDA.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of TLRY is 5.79 and suggests 129% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

02.11.2026 19:00

Alta Banka, a bank popular among Russians in Serbia, has had its license revoked. Where can they open an account?

02.11.2026 18:43

"It's not the time to hide in a bunker": What are people on Wall Street saying after the AI sector's crash?

02.11.2026 17:42

One of the boldest bets: Marvell will acquire optics developer Lumentum for $115 billion

02.11.2026 17:30

Shares of biotech company Inovio soared 240% following the drug's approval. Is there still upside potential?

02.11.2026 17:08

"Hope for a Breakthrough in the Iran Stalemate": Oil Prices Plunge 4%

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026